Anavex Life Sciences Corp.
AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for thā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.95
Price+7.27%
$0.20
1Y
Price
Market Cap
$273.382m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$34.089m
+26.5%
1y CAGR+9.4%
3y CAGR+7.3%
5y CAGREPS
-$0.39
+27.8%
1y CAGR+12.4%
3y CAGR+10.1%
5y CAGRBook Value
$121.707m
$128.766m
Assets$7.059m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$34.075m
+12.7%
1y CAGR-8.3%
3y CAGR-9.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company